Dr. John Cush RheumNow
3 years 7 months ago
UK BADBIR cohort study of 9057 PsA & PsO pts. A greater comorbidity burden and work inability seen PsA vs PsO cohort. PsA (HR 1.98), female sex & depression (HR 1.21) were associated with shorter persistence on ustekinumab. https://t.co/aBILQqXDKl https://t.co/tLNIhnxdXO
Dr. John Cush RheumNow
3 years 7 months ago
Join us! Take advantage of our early bird pricing.
https://t.co/9Up0ZgaRP2
What attendees say about our meeting:
100% found the program free of commercial bias.
99% would recommend RheumNow Live to colleagues.
95% describe the content as extremely relevant to their practice. https://t.co/HOmh0CMyyJ
Dr. John Cush RheumNow
3 years 7 months ago
Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trauma, OA, DISH, acromegaly, fluorosis, retinoid therapy, hypo- or hyper-PTH, POEMS syndrome, X-linked hypophosphatemia https://t.co/pff2OWBT5C https://t.co/7zm2la4GtD
Dr. John Cush RheumNow
3 years 7 months ago
Tofacitinib and RA-ILD
Dr. Richard Conway discusses Abstract 2251 at ACR22 Convergence. Abstract 2251: Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
https://t.co/inndpqqbi8 https://t.co/8tRiKqT1x5
Dr. John Cush RheumNow
3 years 7 months ago
Ferritin may be more than biomarker in Stills, etc - may contribute directly to pathogenesis. Ferritin causes PMN activation & neutrophil extracellular traps (NETs). Could this be targeted therapeutically? https://t.co/yuvMaKqOa7 https://t.co/bjkEJvKH8d
Dr. John Cush RheumNow
3 years 7 months ago
Join RheumNow Live in person or virtually on 3/18 and 3/19. This meeting is unlike any other meeting you attended.
But don't take our word for it, last year's attendees say:
"Great conference. Best in the last year. I did Hopkins, CCR, and ACR too"
https://t.co/jvhKcVXNtz https://t.co/Hc6SzsPKNa
Dr. John Cush RheumNow
3 years 7 months ago
PsA Til Death Do Us Part
Dr. Jack Cush reviews the highlights from the past week on RheumNow
https://t.co/8km1IGdmkZ https://t.co/Drxqq1QYsC
Dr. John Cush RheumNow
3 years 7 months ago
Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
https://t.co/DZ2UxDKgUD https://t.co/tFtNZc1Eza
Dr. John Cush RheumNow
3 years 7 months ago
Poorer health outcomes for at-risk patients with fractures
People at high risk of fracture are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes.
https://t.co/XmFcnBf6US https://t.co/mgAkb0NLBv
Dr. John Cush RheumNow
3 years 7 months ago
Rx failures w/ nonmedical switching of biosimilars may be Nocebo effect. 140 #RA pts, 51 non-switchers & 89 switchers. Non-switchers more likely to improve than switchers (68 vs 26%, p < 0.001) and less likely to worsen (1% vs 9%, p < 0.01). https://t.co/w8lnv1V5Pi https://t.co/iT2RkkSosl
Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.
Dr. John Cush RheumNow
3 years 7 months ago
Naltrexone is indicated in opioid or EtOH dependence - not pain; yet it has wide off-label uses. Shown to be equal to Elavil in Rx of painful DM neuropathy; Little data from PBO RCTs in FM. Unclear how naltrexone modulates pain https://t.co/YZvfbHy9KJ https://t.co/6k9LfQSp1A
Dr. John Cush RheumNow
3 years 7 months ago
What RheumNow Live attendees say about our meeting:
"Great format w/shorter lectures, clinical content, good interface for audience participation to ask questions, and on-demand availability of videos post-meeting."
Join us!
https://t.co/AO0bqP5p54
@Janetbirdope @JoelKreme… https://t.co/d9ZhIbddgh
Inflammatory disorders are often accompanied by an increased mortality risk, either from secondary malignancy, infection or cardiovascular disease. A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality .
